{"filing":{"accession_number":"0001493152-26-032851","cik":"0001859007","ticker":"ZVSA","company_name":"ZyVersa Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/form8-k.htm"},"events":[{"id":17355,"run_id":15535,"accession_number":"0001493152-26-032851","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"Min Chul Park, Ph.D., an independent director and member of two Board committees, resigned effective immediately on July 8, 2026. While the Item 5.02 section also discloses voluntary compensation reductions by the CEO and CFO and explores cost-cutting measures including potential asset divestitures and workforce reductions, the primary disclosed action in the Item 5.02 section is Dr. Park's departure from his director and committee positions. The resignation is material as it represents a change in board composition during a period of financial stress and capital-raising efforts.","company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15796,"accession_number":"0001493152-26-032851","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Min Chul Park, Ph.D., an independent director and member of two Board committees, resigned effective immediately on July 8, 2026. While the Item 5.02 section also discloses voluntary compensation reductions by the CEO and CFO and explores cost-cutting measures including potential asset divestitures and workforce reductions, the primary disclosed action in the Item 5.02 section is Dr. Park's departure from his director and committee positions. The resignation is material as it represents a change in board composition during a period of financial stress and capital-raising efforts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:06:46.676751+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15796,"accession_number":"0001493152-26-032851","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"Min Chul Park, Ph.D., an independent director and member of two Board committees, resigned effective immediately on July 8, 2026. While the Item 5.02 section also discloses voluntary compensation reductions by the CEO and CFO and explores cost-cutting measures including potential asset divestitures and workforce reductions, the primary disclosed action in the Item 5.02 section is Dr. Park's departure from his director and committee positions. The resignation is material as it represents a change in board composition during a period of financial stress and capital-raising efforts.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:06:46.676751+00:00","company_name":"ZyVersa Therapeutics, Inc.","ticker":"ZVSA","filing_date":"2026-07-10"}]}